Novartis confirms filing dates for COPD drugs and progresses programme
This article was originally published in Scrip
Executive Summary
Novartis and Vectura have confirmed US filing dates for two COPD products, QVA149 (end of 2014) and NVA337 (glycopyrronium bromide; beginning of 2014), after reporting that the fourth trial out of the 10 in the Phase III IGNITE programme for QVA149 had met its primary endpoint.